Migraine
The Migraine pipeline: 51 tracked drugs, 41 approved for this indication.
41 approved / phase 43 Phase 31 Phase 2/32 Phase 21 US approval withdrawn3 preclinical / unstaged
Compare the share prices of listed companies in Migraine →
Total attributable cost
$104.7B
$6,575/patient
Drug spend
Not yet sourced
any · US